Back to PFE Stock Lookup

Pfizer (PFE) – Press Releases

Mar 30, 2015 11:00 AM Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit
Mar 26, 2015 10:00 AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
Mar 24, 2015 10:00 AM Pfizer Invites Public To View And Listen To Webcast Of April 28 Conference Call With Analysts
Mar 23, 2015 08:00 AM Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab
Mar 20, 2015 01:00 PM Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials
Mar 18, 2015 05:04 PM Results of Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine
Mar 18, 2015 10:39 AM Help Protect Texas' Babies: Make sure your children are fully vaccinated
Mar 12, 2015 04:30 PM Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia
Mar 11, 2015 02:34 PM A.M. Best Affirms Ratings of Blue Whale Re Ltd.
Mar 3, 2015 08:35 AM Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults
Feb 26, 2015 12:29 PM CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk
Feb 25, 2015 08:00 AM Nodality Inc. Presents Data from Immuno-Oncology Program Applying Company’s Novel Single Cell Network Profiling (SCNP) Platform
Feb 24, 2015 10:00 AM Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Feb 24, 2015 08:00 AM Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA® (Meningococcal Group B Vaccine) Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertu
Feb 20, 2015 10:30 AM FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)
Feb 13, 2015 10:27 AM Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride)
Feb 9, 2015 05:27 PM Pfizer Commences $5 Billion Accelerated Share Repurchase
Feb 9, 2015 10:00 AM Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Investor Conference
Feb 5, 2015 06:19 PM Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Hospira, Inc. Stockholders
Feb 5, 2015 07:10 AM Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Pfizer’s Proposed Acquisition of Hospira
Feb 5, 2015 07:00 AM Pfizer To Acquire Hospira
Feb 4, 2015 03:22 PM Pfizer Announces FDA Acceptance For Review Of Supplemental New Drug Application For Oral XELJANZ® (tofacitinib citrate) For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis
Feb 4, 2015 09:30 AM ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men
Feb 4, 2015 08:00 AM Pfizer Marks World Cancer Day with Grant to Union for International Cancer Control to Address the Needs of Metastatic Breast Cancer Patients
Feb 3, 2015 06:00 PM Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE® (palbociclib)
Jan 29, 2015 08:15 AM OPKO and Pfizer Receive Regulatory Clearance for Global Agreement
Jan 27, 2015 07:00 AM PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE
Jan 26, 2015 04:12 PM Pfizer Commits to Further Reduce Price for Prevenar 13 in the World’s Poorest Countries Through 2025
Jan 22, 2015 11:21 AM Prevenar 13®* Receives CHMP Positive Opinion For Prevention Of Vaccine-Type Pneumococcal Pneumonia in Adults
Jan 8, 2015 08:30 AM Pfizer Provides Update on IBRANCE® (palbociclib)
Jan 7, 2015 08:00 AM Nodality Launches PathPro™ Product Line Based on Leading Single Cell Network Profiling (SCNPTM) Platform to Enhance Pharmaceutical R&D
Jan 6, 2015 10:00 AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
Jan 5, 2015 07:30 AM Pfizer Acquires Redvax GmbH
May 19, 2014 08:05 AM Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability Index
Jan 13, 2014 08:00 AM Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With

Back to PFE Stock Lookup